Compare Stocks: PRME, BEAM, ADMA, and PVLA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$9.90	$8.63	$7.21 ▼ $20.46	$2.29B	0.74	2.80 million shs	3.30 million shs
BEAM Beam Therapeutics	$27.48	$30.61	$15.60 ▼ $38.26	$2.84B	2.23	1.98 million shs	1.32 million shs
PRME Prime Medicine	$3.08	$3.28	$2.67 ▼ $6.94	$556.30M	2.31	2.87 million shs	1.97 million shs
PVLA Palvella Therapeutics	$157.77	$133.76	$38.95 ▼ $161.38	$2.27B	-0.17	210,317 shs	182,299 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	0.00%	+17.02%	+9.03%	+25.63%	-40.07%
BEAM Beam Therapeutics	0.00%	+7.68%	-15.91%	-13.45%	+55.96%
PRME Prime Medicine	0.00%	+5.48%	-18.52%	-4.94%	-78.42%
PVLA Palvella Therapeutics	0.00%	+13.47%	+8.99%	+29.22%	+285.75%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$9.90	$8.63	$7.21 ▼ $20.46	$2.29B	0.74	2.80 million shs	3.30 million shs
BEAM Beam Therapeutics	$27.48	$30.61	$15.60 ▼ $38.26	$2.84B	2.23	1.98 million shs	1.32 million shs
PRME Prime Medicine	$3.08	$3.28	$2.67 ▼ $6.94	$556.30M	2.31	2.87 million shs	1.97 million shs
PVLA Palvella Therapeutics	$157.77	$133.76	$38.95 ▼ $161.38	$2.27B	-0.17	210,317 shs	182,299 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	0.00%	+17.02%	+9.03%	+25.63%	-40.07%
BEAM Beam Therapeutics	0.00%	+7.68%	-15.91%	-13.45%	+55.96%
PRME Prime Medicine	0.00%	+5.48%	-18.52%	-4.94%	-78.42%
PVLA Palvella Therapeutics	0.00%	+13.47%	+8.99%	+29.22%	+285.75%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMA ADMA Biologics	2.33	Hold	$18.67	88.55% Upside
BEAM Beam Therapeutics	2.69	Moderate Buy	$49.00	78.31% Upside
PRME Prime Medicine	2.88	Moderate Buy	$7.53	144.52% Upside
PVLA Palvella Therapeutics	3.00	Buy	$209.14	32.56% Upside

Current Analyst Ratings Breakdown

Latest PRME, BEAM, ADMA, and PVLA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/5/2026	PVLA Palvella Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$207.00
8/5/2026	PVLA Palvella Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$232.00
8/4/2026	ADMA ADMA Biologics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/28/2026	PVLA Palvella Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/22/2026	PVLA Palvella Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$270.00
7/17/2026	BEAM Beam Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	ADMA ADMA Biologics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$20.00 ➝ $17.00
7/8/2026	PRME Prime Medicine	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/8/2026	BEAM Beam Therapeutics	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$47.00
7/7/2026	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$80.00
7/6/2026	ADMA ADMA Biologics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold

(Data available from 8/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMA ADMA Biologics	$510.17M	4.50	$0.65 per share	15.14	$2.01 per share	4.93
BEAM Beam Therapeutics	$139.74M	20.31	N/A	N/A	$12.20 per share	2.25
PRME Prime Medicine	$4.07M	136.58	N/A	N/A	$0.67 per share	4.60
PVLA Palvella Therapeutics	$42.81M	53.11	N/A	N/A	$2.36 per share	66.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMA ADMA Biologics	$146.93M	$0.70	14.14	11.79	N/A	32.98%	40.17%	26.97%	N/A
BEAM Beam Therapeutics	-$79.99M	-$0.86	N/A	N/A	N/A	-54.75%	-30.71%	-24.07%	N/A
PRME Prime Medicine	-$201.14M	-$1.06	N/A	N/A	N/A	-4,613.11%	-156.84%	-55.13%	N/A
PVLA Palvella Therapeutics	-$41.72M	-$4.83	N/A	N/A	N/A	N/A	-47.84%	-38.33%	N/A

Latest PRME, BEAM, ADMA, and PVLA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	PRME Prime Medicine	-$0.24	-$0.24	N/A	-$0.24	$4.40 million	$1.15 million
8/5/2026	Q2 2026	ADMA ADMA Biologics	$0.1633	$0.16	-$0.0033	$0.16	$125.34 million	$124.40 million
8/4/2026	Q2 2026	BEAM Beam Therapeutics	-$1.11	-$1.18	-$0.07	-$1.18	$16.37 million	$0.49 million
8/4/2026	Q2 2026	PVLA Palvella Therapeutics	-$1.17	-$1.52	-$0.35	-$1.52	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
PRME Prime Medicine	$1.45	46.95%	N/A	N/A	N/A
PVLA Palvella Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMA ADMA Biologics	0.49	6.97	3.81
BEAM Beam Therapeutics	0.09	14.57	14.57
PRME Prime Medicine	N/A	3.80	3.80
PVLA Palvella Therapeutics	N/A	21.18	21.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADMA ADMA Biologics	75.68%
BEAM Beam Therapeutics	99.68%
PRME Prime Medicine	70.37%
PVLA Palvella Therapeutics	40.11%

Insider Ownership

Company	Insider Ownership
ADMA ADMA Biologics	3.90%
BEAM Beam Therapeutics	3.80%
PRME Prime Medicine	16.04%
PVLA Palvella Therapeutics	17.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMA ADMA Biologics	530	231.77 million	222.73 million	Optionable
BEAM Beam Therapeutics	510	103.29 million	99.36 million	Optionable
PRME Prime Medicine	N/A	180.62 million	152.28 million	N/A
PVLA Palvella Therapeutics	N/A	14.41 million	11.93 million	N/A

PRME, BEAM, ADMA, and PVLA Headlines

Recent News About These Companies

Palvella Therapeutics, Inc. $PVLA Shares Purchased by The Manufacturers Life Insurance Company

August 9 at 4:48 AM | marketbeat.com

HC Wainwright Issues Pessimistic Forecast for PVLA Earnings

August 9 at 1:14 AM | americanbankingnews.com

Is Palvella Therapeutics (PVLA) Fully Valued Ahead Of QTORIN Approval?

August 8 at 1:19 PM | finance.yahoo.com

Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Consensus Rating of "Buy" from Analysts

August 7 at 6:28 AM | marketbeat.com

Q3 EPS Estimate for Palvella Therapeutics Cut by Analyst

August 7 at 6:11 AM | marketbeat.com

Palvella Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation

August 5, 2026 | seekingalpha.com

Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

August 5, 2026 | globenewswire.com

Palvella Therapeutics Charts Clear Path From Data To Launch

August 4, 2026 | tipranks.com

Palvella Therapeutics, Inc. (PVLA) Q2 2026 Earnings Call Transcript

August 4, 2026 | seekingalpha.com

Full Transcript: Palvella Therapeutics Q2 2026 Earnings Call

August 4, 2026 | benzinga.com

Palvella Therapeutics Q2 Earnings Call Highlights

August 4, 2026 | marketbeat.com

Palvella Therapeutics (NASDAQ:PVLA) Posts Quarterly Earnings Results, Misses Expectations By $0.35 EPS

August 4, 2026 | marketbeat.com

Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 4, 2026 | globenewswire.com

Arete Wealth Advisors LLC Makes New $2.18 Million Investment in Palvella Therapeutics, Inc. $PVLA

August 1, 2026 | marketbeat.com

Palvella Therapeutics, Inc. $PVLA Shares Bought by Avidity Partners Management LP

August 1, 2026 | marketbeat.com

Chardan Capital Upgrades Palvella Therapeutics (NASDAQ:PVLA) to Strong-Buy

July 31, 2026 | marketbeat.com

Palvella Therapeutics (PVLA) Expected to Post Quarterly Earnings on Tuesday

July 30, 2026 | marketbeat.com

Palvella Therapeutics to Provide Public Comment at FDA Meeting on Drug Repurposing Criteria and Prioritization

July 30, 2026 | quiverquant.comQ

Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing

July 30, 2026 | globenewswire.com

Arete Wealth Advisors LLC Takes Position in Palvella Therapeutics, Inc. $PVLA

July 30, 2026 | marketbeat.com

Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update ...

July 28, 2026 | caledonianrecord.comC

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRME, BEAM, ADMA, and PVLA Company Descriptions

ADMA Biologics NASDAQ:ADMA

$9.90 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$9.90 -0.01 (-0.05%)

As of 08/7/2026 07:34 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Beam Therapeutics NASDAQ:BEAM

$27.48 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$27.70 +0.22 (+0.78%)

As of 08/7/2026 07:45 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Prime Medicine NASDAQ:PRME

$3.08 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$3.09 +0.01 (+0.32%)

As of 08/7/2026 07:59 PM Eastern

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. Genetic mutations implicated in disease are diverse and can range from errors of a single base, known as point mutations, to errors that extend beyond a single base, such as insertions, deletions, duplications, or combinations thereof. We believe the ability to alter the human genome at the foundational level may confer the greatest therapeutic impact on human disease. Gene editing, including platforms such as Prime Editing, is a novel technology that is not yet clinically validated for human therapeutic use. Over the last decade, the field of genetic medicine has evolved tremendously, with groundbreaking advances in gene therapy, cell therapy, RNA therapy, and, more recently, gene editing. These technologies represent dramatic advancements for genetic therapies, but lack the versatility to precisely and efficiently correct the diverse range of mutations or DNA alterations implicated in disease. Prime Medicine was co-founded by a world-renowned leader in the field of gene editing, David Liu, Ph.D. Dr. Liu was joined as co-founder by Andrew Anzalone, M.D., Ph.D., who conceived of and developed Prime Editing technology. Drawn by the promise of Prime Editing’s ability to transform the field of gene editing, we have assembled a diverse team that has grown to more than 150 people as of September 30, 2022. There are no current plans for Dr. Liu to be an officer or director of our company following this offering. He is expected to continue to provide consulting services to us pursuant to a consulting agreement, which has a current term that runs through September 2025 and accommodates a previous commitment with respect to Beam Therapeutics Inc., which could result in or may create the appearance of a conflict of interest. He is also expected to retain his position and affiliation with the Broad Institute, Inc., Howard Hughes Medical Institute and Harvard University. On September 20, 2022, we achieved a major milestone as the United States Patent and Trademark Office, or the USPTO, issued U.S. Patent 11,447,770, or the ‘770 Patent, covering methods of using Prime Editors. The Broad Institute, Inc., or Broad Institute, prepared, filed and prosecuted the ‘770 Patent. While Broad Institute is the owner of the ‘770 Patent, it is exclusively licensed to us under the terms of the license agreement with Broad Institute. The ‘770 Patent is the first issued Prime Editing patent in our licensed patent portfolio and we believe it will be instrumental in protecting our Prime Editing platform and pipeline of gene editing programs. We believe our in-licensed and company-owned Prime Editing technology has transformative potential that could change the course of how disease is treated and overcome the challenges associated with current genetic therapies. We in-license our Prime Editing technology pursuant to a license agreement with Broad Institute. In addition, the license agreement grants us certain rights and licenses under certain patent rights Broad Institute owns or controls, including a license to the ‘770 Patent, which covers Prime Editing technology and expires in 2040. The licenses are limited to the field of prevention or treatment of human disease, and most licenses granted to us under the license agreement are further limited to the prevention or treatment of human disease by editing (including modifying or converting) or targeting DNA ex vivo, in vivo, or through xeno transplantation methods, which we refer to as the Prime Broad Field. We were incorporated under the laws of the State of Delaware in September 2019 under the name Prime Medicine, Inc. Our principal executive offices are located at 21 Erie Street, Cambridge, MA.

Palvella Therapeutics NASDAQ:PVLA

$157.77 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$157.78 +0.01 (+0.01%)

As of 08/7/2026 07:34 PM Eastern

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PRME, BEAM, ADMA, and PVLA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PRME, BEAM, ADMA, and PVLA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PRME, BEAM, ADMA, and PVLA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRME, BEAM, ADMA, and PVLA Company Descriptions

ADMA Biologics NASDAQ:ADMA

Beam Therapeutics NASDAQ:BEAM

Prime Medicine NASDAQ:PRME

Palvella Therapeutics NASDAQ:PVLA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PRME, BEAM, ADMA, and PVLA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PRME, BEAM, ADMA, and PVLA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PRME, BEAM, ADMA, and PVLA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRME, BEAM, ADMA, and PVLA Company Descriptions

ADMA Biologics NASDAQ:ADMA

Beam Therapeutics NASDAQ:BEAM

Prime Medicine NASDAQ:PRME

Palvella Therapeutics NASDAQ:PVLA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools